- Previous Close
150.22 - Open
149.85 - Bid 151.84 x 1100
- Ask 152.20 x 800
- Day's Range
149.38 - 152.12 - 52 Week Range
125.64 - 179.60 - Volume
88,013 - Avg. Volume
898,583 - Market Cap (intraday)
12.165B - Beta (5Y Monthly) 0.99
- PE Ratio (TTM)
14.17 - EPS (TTM)
10.73 - Earnings Date Apr 30, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
163.26
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
www.davita.com76,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DVA
View MorePerformance Overview: DVA
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DVA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DVA
View MoreValuation Measures
Market Cap
12.02B
Enterprise Value
23.24B
Trailing P/E
14.00
Forward P/E
13.62
PEG Ratio (5yr expected)
2.06
Price/Sales (ttm)
1.02
Price/Book (mrq)
99.22
Enterprise Value/Revenue
1.81
Enterprise Value/EBITDA
8.53
Financial Highlights
Profitability and Income Statement
Profit Margin
7.31%
Return on Assets (ttm)
7.15%
Return on Equity (ttm)
51.74%
Revenue (ttm)
12.82B
Net Income Avi to Common (ttm)
936.34M
Diluted EPS (ttm)
10.73
Balance Sheet and Cash Flow
Total Cash (mrq)
846M
Total Debt/Equity (mrq)
576.99%
Levered Free Cash Flow (ttm)
1.18B